Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002569 · ClinicalTrials.gov registry record · Phase 3

Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma

A Phase 3 study, sponsored by Radiation Therapy Oncology Group.

Completed
Registry status
Phase 3
Development phase
299
Enrollment target

NCT00002569 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 299 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002569, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.

COMPLETED
Registry status
Phase 3
Development phase
299 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without chemotherapy in treating patients who have anaplastic oligodendroglioma.

Interventions

  • RADIATION radiation therapy
  • DRUG vincristine sulfate
  • DRUG lomustine
  • DRUG procarbazine hydrochloride

Trial Details

FieldValue
Enrollment Target 299 participants
Start Date 1994-07
Est. Completion 2018-05-21
Phase Phase 3

Sponsor

Radiation Therapy Oncology Group

144 total trials

What the Registry Record Tells You About NCT00002569

The ClinicalTrials.gov registry entry for NCT00002569 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 299 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which radiation therapy is the first listed.

NCT00002569 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00002569 about?

NCT00002569 is a clinical study titled "Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Randomized phase III trial to co...

What is the current status of trial NCT00002569?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 299 participants. The study started on 1994-07. Estimated completion is 2018-05-21.

What interventions are being tested in trial NCT00002569?

The interventions under investigation include: radiation therapy (RADIATION), vincristine sulfate (DRUG), lomustine (DRUG), procarbazine hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00002569?

This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.